Editors' Message
It is our pleasure to welcome you all to the 66th annual meeting of the American Society of Hematology. Once again in sunny San Diego, we hope you enjoy reconnecting with colleagues, forging new collaborations, and discovering the incredible advances in hematology at the meeting this year. Hematology is intended to be your lasting educational companion for the meeting and beyond, and we have striven to make this version of the publication the highest-quality one yet in its over 5-decade history. Every article has been written by vetted international experts in their field, rigorously peer reviewed, and carefully edited to deliver a focused, up-to-date, and superior educational experience. Once again included by popular demand are a series of Evidence-Based Minireviews, short articles tackling many of the most pressing clinical questions we face in daily hematology practice. Whether you practice primarily classical hematology, malignant hematology, or the whole breadth of hematology, we hope that this year’s edition will again serve you well. Once again, also by popular demand, a print version is available for sale for those who prefer a physical book.
As always, we are thankful for the Education Program cochairs, Dr. Rakhi Naik (classical hematology; bonus points for serving double duty as an Education Program cochair and Hematology deputy editor!) and Dr. John Koreth (malignant hematology), for developing a state-of-the-art education program on which this volume is based. Additionally, Hematology is possible only thanks to the efforts of more than 150 invaluable peer reviewers and the diligent efforts of the ASH publications staff, including Glenn Landis, Ebony Stewart, Alison Beale, Jeremiah Murphy, Dax Rodulfa-Blemberg, Brian Cannon, Kenneth April, Sera Johnson, and Nina Hoffman, among others. We are so thankful for all of their hard work and dedication.
Finally, as our terms come to an end as Editors of Hematology, we thank you all for your support and your appreciation for this venerable and indispensable tome. It was our pleasure to do our part to make it all come together for the past 3 years.
Enjoy, from your Hematology Editors!
Editors
Hanny Al-Samkari, MD, Executive Editor, is an associate professor of medicine at Harvard Medical School. He is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital, where he practices adult classical hematology and directs the Massachusetts General Hospital Hereditary Hemorrhagic Telangiectasia Center of Excellence. His research focuses on the development of novel therapeutics in hereditary hemorrhagic telangiectasia, immune thrombocytopenia, and congenital red cell disorders. He additionally does research on the alleviation of hematologic adverse effects of cancer treatment.
Alison R. Walker, MD, MPH, MBA, Deputy Editor, is a professor of oncologic sciences at the University of South Florida and a member of the Department of Malignant Hematology at H. Lee Moffitt Cancer Center & Research Institute, where she serves as chief of the Medical Oncology Service Line and is the physician practice advisor to the Moffitt Medical Group. Dr. Walker’s clinical and research interests are in the care of patients with myeloid malignancies, specifically acute myeloid leukemia and myelodysplastic syndromes.
Rakhi P. Naik, MD, MHS, Deputy Editor, is an associate professor of medicine at Johns Hopkins University, where she serves as clinical director of the Division of Hematology and associate program director for the Hematology Fellowship Track. Dr. Naik’s research focuses on sickle cell disease, sickle cell trait, and medical education innovation.
Alex F. Herrera, MD, Deputy Editor, is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California. His clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with Hodgkin or non-Hodgkin lymphomas. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation with the goal of designing biomarker-based clinical trials to improve outcomes and personalize lymphoma treatment.
Ang Li, MD, MS, Special Section Editor, is an assistant professor at Baylor College of Medicine, a member of the Dan L Duncan Comprehensive Cancer Center, and a Cancer Prevention & Research Institute of Texas (CPRIT) Scholar. Clinically, he specializes in the care of patients with thrombotic and bleeding disorders. As a physician-scientist, he focuses on the epidemiology, prevention, and treatment of venous thromboembolism and thrombotic microangiopathy in association with cancer treatment and hematopoietic cell transplantation.
Editor Conflict of Interest Disclosures
